Results of Polish medical centres within an international randomized phase III study of docetaksel plus cisplatin and docetaksel plus carboplatin versus winorelbine plus cisplatin for advanced non-small-cell lung cancer;Doświadczenia polskich ośrodków w ramach miȩdzynarodowego randomizowanego badania III fazy z zastosowaniem schematów dwulekowych: Docetakselu i cisplatyny oraz doksetakselu i karboplatyny w porównaniu z poła̧czeniem winorelbiny z cisplatyna̧ w zaawansowanym raku niedrobnokomórkowym płuca

Nowotwory

Volumn 57, Issue 2, 2007, Pages 146-152

  Ramlau, Rodryg ^a,g   Płuzańska, Anna ^b   Szczȩsna, Aleksandra ^c   Karnicka Młodkowska, Hanna ^d   Wojtukiewicz, Marek ^e   Oklek, Kazimierz ^f   Folcik, Krystyna ^d   Galȩba, Anna ^a   Spychalski, Łukasz ^a  

^a Oddzia Onkologii Klinicznej WCChPiG   (Poland)

^b Klinika Onkologii UM   (Poland)

^c Oddzia Pulmonologiczny Mazowieckie Centrum LChPiG   (Poland)

^d Oddział Onkologiczny Szpital Morski ^*

^e Białostockie Centrum Onkologii   (Poland)

^f Klinika Chorób P uc I Gru licy AM   (Poland)

^g GREATER POLAND CANCER CENTRE   (Poland)

Author keywords

Chemotherapy; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; NAVELBINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POLAND; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34250731320     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Wojciechowska U, Didkowska I, Tarkowski W i wsp. Nowotwory złośliwe w Polsce w 2003 roku. Warszawa: Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, 2005.
2. WHO. World health statistics annual 1996. WHO, Genewa 1998.
3. Jassem J, Drosik K, R. Dziadziuszko R i wsp. Zalecenia dotycza̧ce systemowego leczenia niedrobnokomórkowego raka płuca i złosliwego miȩdzybtoniaka opłucnej: konferencja okra̧głego stołu. Nowotwory J Oncol 2005; 55: 160-6.
4. Fossella F, Pereira JR, Pavel von J i wsp. Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non-Small-Cell Lung Cancer: TAX 326 Study Group
5. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 1431-41.
6. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
7. Delbado C i wsp. Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small-cell lung carcinoma (NSCLC): a meta-analysis of the literature. Proc Am Soc Clin Oncol 2003; 22: 624 abstract 2510.
8. Katshuyuki H i wsp. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung career. J Clin Oncol 2004; 22: 3852-59.
9. Le Chevalier T, Brissgand D, Douillard JY i wsp. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non - small cell lung cancer: Results of European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7.
10. Livingston RB. Current managementof unresectable non-small-cell lung cancer. Oncology 1997; 11 suppl 12: 11-5.
11. Kelly K. Crowley J, Bunn PA Jr. Ct at. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. I Clin Oncol 2001; 19: 3210-8.
12. Scagliotti GV, De Marinis F, Rinaldi M i wsp. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-91.
13. Wozniak AJ, Crowley JJ, Balcerzak SP i wsp: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459-65.
14. Bonomi P, Kim KM, Fainlough D i wsp. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of pacitaxel combined with cisplatn versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623-31.
15. Rosell R, Gatzemeier U, Betticher DC i wsp. Phase III randomised trial comparing paclitaxell/carboplatin with paclitaxell/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 2002; 13: 1539-49.
16. Albain KS, Crowley JJ, LeBlanc M i wsp. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-26.
17. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995; 75: 968-72.
18. Gandara DR. Crowley I, Livingston RB i wsp. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. 3 Cliii Oncol 1993; 11: 873-8.